Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
The national consumer disputes redressal commission (NCDRC) has upheld the Rajasthan state consumer commission’s finding of ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...
The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...
Your dog sneezed 9 times before breakfast: harmless autumn itch or a £65 vet bill waiting to happen?
Cold mornings, radiators humming, and a chorus of snorts from the sofa raise quiet doubts in countless British homes. As ...
Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
The holiday season brings family gatherings and frequent travel — but for many Scottsdale residents, it also brings sinus ...
Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.
A collaborative study between Texas A&M University’s School of Engineering Medicine (EnMed) and Houston Methodist Hospital’s Department of Otolaryngology – Head and Neck Surgery is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback